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Abstract. In a group sequential clinical trial, accumulated data are analysed
at numerous time-points in order to allow early decisions about a hypothesis of
interest. These designs have historically been recommended for their ethical, ad-
ministrative and economic benefits. In this work, we discuss a collection of new
Stata commands for computing the stopping boundaries and required group size
of various classical group sequential designs, assuming a normally distributed out-
come variable. Following this, we demonstrate how the performance of several
designs can be compared graphically.
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1 Introduction
Parallel group randomised controlled trials are typically conducted by recruiting a fixed
number of individuals and allocating each to receive one of two treatments, ultimately
testing a pre-specified hypothesis. Since Wald published his work on the sequential
probability ratio test (Wald 1947), there has been substantial interest in trial designs
that allow hypotheses to be tested multiple times during the trial. With this approach,
the trial may be stopped early if the data so suggests. This leads to patient exposure to
inferior treatments being limited, and, by helping to lower the expected required sample
size, the cost of a trial will often be reduced.
Armitage (1975) was responsible for much of the early use of such methods in
medicine. However, his and the other initial approaches were fully sequential, with
data analysed after every patient. Whilst this may seem desirable, it is impractical and
thus this methodology did not gain general acceptance. The pivotal moment in this
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field came with the work of Pocock (1977), who provided a clear way of determining
group sequential designs with desired type-I and type-II error rates. In a group sequen-
tial design, a hypothesis is analysed multiple times during an on going trial, but as the
name suggests, only after groups of certain sizes have been assessed. This allows the
majority of the benefits of a fully sequential approach to be retained, whilst also making
the design feasible in practice.
Since this paper, group sequential designs have been researched extensively, and
utilised regularly in clinical trials. Today, methodology is well established for designing
group sequential trials with normal, binary, and survival endpoints. Approaches are
available to design trials with unknown variance, with multiple arms, or to optimise a
designs features. For a detailed discussion of available methods see Whitehead (1997)
or Jennison and Turnbull (2000).
In this paper, we focus on the design of two-treatment group sequential trials with
a normally distributed outcome variable, but note that asymptotically other endpoint
types can be treated with the same normal test statistics. We proceed by summarising
the statistical theory behind group sequential methodology. Following this we detail
our new commands, and provide several examples of their use.
2 Statistical Theory
We consider a randomised two-arm group sequential trial design with up to L planned
analyses. We index one arm by 0, and the other by 1. Often, it will be the case that arm
0 is a control and arm 1 an experimental treatment, but this may not always be true.
We assume that the lth analyses takes place after n0l = ln and n1l = rln patients have
been randomised to arms 0 and 1, respectively. Possible extensions to this framework
are discussion in Section 8. Thus r is the ratio of patients allocated to arm 1 relative
to arm 0, and we refer to n as the group size. The outcome from patient i in arm d in
stage l , Ydli, is assumed to be distributed as follows
Ydli ∼ N(µd, σ2d).
Thus, we are assuming that the variance in response of both treatments is known.
Our ultimate goal is to make inference about the difference in the average treatment
effect of arms 0 and 1. To this end, we define τ = µ1− µ0, and at each interim analysis
l compute the following test-statistic
Zl =
 1
n1l
l∑
j=1
rn∑
i=1
Y1ji − 1
n0l
l∑
j=1
n∑
i=1
Y0ji
 I1/2l ,
with
Il =
(
σ20
n0l
+
σ21
n1l
)−1
=
(
σ20
ln
+
σ21
rln
)−1
, (1)
the information for this analysis. It can be shown that {Z1, . . . , ZL} have for the
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parameter of interest τ , with information levels {I1, . . . , IL}, what has been referred to
as the canonical joint distribution (Jennison and Turnbull 2000). That is
• (Z1, . . . , ZL) is multivariate normal;
• E(Zl) = τI1/2l , l = 1, . . . , L;
• cov(Zl1 , Zl2) = (Il1/Il2)1/2, 1 ≤ l1 ≤ l2 ≤ L.
Using this, the operating characteristics of a group sequential design with any choice
of stopping boundaries can be determined using multivariate normal integration as de-
scribed in Jennison and Turnbull (2000) and Wason (2015a). This allows the use of
numerical optimisation routines to determine suitable sample sizes and stopping bound-
aries. The particular type of boundaries to utilise depends on the chosen hypothesis
testing framework. Therefore, in the following sections we discuss several established
methods for two-sided, and then one-sided, tests.
3 Two-Sided Tests
3.1 Stopping Rules and Operating Characteristics
In a two-sided test, we assess whether there is significant evidence of a difference in the
mean responses of the two treatment arms. That is, we test
H0 : τ = 0, H1 : τ 6= 0.
Here, a group sequential trial design is characterised by stopping boundaries a1, . . . , aL
and r1, . . . , rL, with 0 ≤ al < rl for l = 1, . . . , L − 1, and aL = rL, and the following
stopping rules at analyses l = 1, . . . , L
• If |Zl| ≥ rl stop and reject H0;
• If |Zl| < al stop and do not reject H0;
• otherwise continue to stage l + 1.
The choice aL = rL ensures termination after analysis L, whilst also guaranteeing a
conclusion is made about H0.
Then, the probability of rejecting H0 for any τ , given n, is
P (Reject H0 | τ) =
L∑
l=1
P (Reject H0 at stage l | τ),
= P (|Z1| ≥ r1 | τ)
+
L∑
l=2
P (a1 ≤ |Z1| < r1, . . . , al−1 ≤ |Zl−1| < rl−1, |Zl| ≥ rl | τ).
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Similarly, the probability of not rejecting H0 for any τ is
P (Accept H0 | τ) =
L∑
l=1
P (Accept H0 at stage l | τ),
= P (|Zl| < al | τ)
+
L∑
l=2
P (a1 ≤ |Z1| < r1, . . . , al−1 ≤ |Zl−1| < rl−1, |Zl| < al | τ).
Using the above, the expected sample size for any τ can be calculated as
E(N | τ) =
L∑
l=1
{P (Reject H0 at stage l | τ) + P (Accept H0 at stage l | τ)} (ln+ rln).
As discussed earlier, each of these probabilities can be computed using multivariate
normal integration. Explicitly, defining
Λl =
cov(Z1, Z1) . . . cov(Z1, Zl)... . . . ...
cov(Zl, Z1) . . . cov(Zl, Zl)
 ,
I l = (I1, . . . , Il)
T ,
then, for example
P (Reject H0 at stage 2 | τ) =
∫ −a1
−r1
∫ −r2
−∞
φ{x, τI1/22 ,Λ2} dx2dx1
+
∫ −a1
−r1
∫ ∞
r2
φ{x, τI1/22 ,Λ2} dx2dx1
+
∫ r1
a1
∫ −r2
−∞
φ{x, τI1/22 ,Λ2} dx2dx1
+
∫ r1
a1
∫ ∞
r2
φ{x, τI1/22 ,Λ2} dx2dx1.
Here, x = (x1, x2)
T , the square root of the vector I2 is taken in an element wise manner,
and φ{x,µ,Λ} is the probability density function of a multivariate normal distribution
with mean µ and covariance matrix Λ, evaluated at vector x. In all of the commands
presented here, these integrals are evaluated using the mata function pmvnormal mata()
(Grayling and Mander 2016).
With the above specifications, all that remains is a method for determining stopping
boundaries, and an associated required sample size, such that P (Reject H0 | 0) ≤ α and
P (Reject H0 | ±δ) ≥ 1 − β, for clinically relevant difference δ > 0, and desired type-I
and type-II error rates α and β. It is this problem that much of the group sequential
clinical trial design literature has focused upon. In the following sections we discuss
several options available via our commands.
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3.2 Early Stopping to Reject H0
Much of the early work on group sequential trial design focused on two-sided tests with
early stopping only to reject H0. That is, with al = 0 for l = 1, . . . , L−1. In particular,
Haybittle (1971) and Peto et al. (1976) suggested a simple set of boundaries with rl = 3
for l = 1, . . . , L − 1. The final critical boundary rL is then determined to ensure an
overall type-I error rate of α. Following the determination of rL, a one-dimensional
numerical search is utilised to ascertain the exact required group size n for power of
1− β when τ = ±δ, treating n as a continuous quantity.
Haybittle and Peto’s procedure is advantageous in that it is a simple one, whilst its
wide stopping boundaries mean that early stopping is unlikely: a desirable property in
some instances to help increase data accumulation, with termination only in the case
of extreme disparities in treatment performance. However, trialists will often desire
stopping boundaries that help to substantially reduce the expected sample size when
H0 is not true. For this, Wang and Tsiatis (1987) suggested the following family of
stopping boundaries, indexed by a parameter Ω
rl = CWT (l/L)
Ω−1/2.
Their procedure encompasses the popular Pocock (1977) and O’Brien and Fleming
(1979) boundaries, by taking Ω = 0.5 or Ω = 0 respectively. In this approach, a
numerical search is utilised for any chosen Ω to determine the value of CWT that implies
the correct type-I error rate α. Following this, as with Haybittle and Peto’s design, a
further search is then used to ascertain the required sample size for the power constraint.
In general, it has been shown that as Ω increases, the maximum sample size increases,
but the expected sample size for larger values of |τ | decreases.
Later, we present commands haybittlePeto and wangTsiatis for determining the
stopping boundaries and required sample size of these designs for any choice of L, σ20 ,
σ21 , δ, α, β and Ω.
3.3 Early Stopping to Reject and Not Reject H0
The above designs deal well with the issue of ethics in two-sided clinical trials; namely
the desire to stop early when the difference between treatments is substantial. However,
there are also often sound reasons to desire early stopping when it is clear there is
no detectable treatment difference; usually based around reducing the cost of a trial.
These are trial designs with not all al = 0, l = 1, . . . , L − 1. Pampallona and Tsiatis
(1994) described a one-parameter family of such trial designs, again indexed by a shape
parameter Ω, that has been referred to as the power family of inner wedge designs.
Explicitly
rl = Cr(l/L)
Ω−1/2,
al = δI
1/2
l − Ca(l/L)Ω−1/2.
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The final information level is then
IL =
(Ca + Cr)
2
δ2
,
to ensure aL = rL as desired. A two-dimensional numerical search is utilised to deter-
mine the values of Ca and Cr that provide the desired type-I and type-II error rates
given choices for L, α, β and Ω. With these values identified, the final required informa-
tion level IL is used to determine the exact required group size n through Equation (1).
As in the procedure of Wang and Tsiatis (1987) above, the inclusion of the parameter
Ω allows a large range of designs to be determined, with varying performance in terms
of their expected sample sizes. In Section 6 we will see how these performances can be
examined graphically.
Alternatively, Whitehead and Stratton (1983) and Whitehead (1997) proposed an
approach for the determination of a group sequential clinical trial design for a two-sided
test with early stopping to not reject H0, termed the double triangular test. Specifically,
they demonstrated that a design with
rl =
{
2
δ˜
log
(
1
α
)
− 0.583
(
IL
L
)1/2
+
δ˜
4
l
L
IL
}
1
I
1/2
l
,
al = max
{[
−2
δ˜
log
(
1
α
)
+ 0.583
(
IL
L
)1/2
+
3δ˜
4
l
L
IL
]
1
I
1/2
l
, 0
}
,
where
δ˜ =
2z1−α/2δ
z1−α/2 + z1−β
,
and
IL =
[{
4(0.583)2
L
+ 8 log
(
1
α
)}1/2
− 2(0.583)
L1/2
]2
1
δ˜
,
would approximately attain a type-I error rate of α when τ = 0, and a type-II error
rate of β when τ = ±δ.
Later, we discuss our commands innerWedge and doubleTriangular for determin-
ing these designs.
4 One-Sided Tests
4.1 Stopping Rules and Operating Characteristics
In a one-sided test, we assess whether, without loss of generality, the mean response on
treatment 1 is significantly larger than that on treatment 0. That is, we test
H0 : τ ≤ 0, H1 : τ > 0.
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A group sequential trial design of this type is characterised by stopping boundaries
f1, . . . , fL and e1, . . . , eL, with fl < el for l = 1, . . . , L − 1 and fL = eL, and the
following stopping rules at analyses l = 1, . . . , L
• If Zl ≥ el stop and reject H0,
• If Zl < fl stop and do not reject H0,
• otherwise continue to stage l + 1,
Again, the choice fL = eL is to ensure termination after analysis L, and to guarantee a
conclusion is drawn about H0.
Now, the probability of rejecting H0 for any τ , given n, becomes
P (Reject H0 | τ) =
L∑
l=1
P (Reject H0 at stage l | τ),
= P (Zl ≥ el | τ)
+
L∑
l=2
P (f1 ≤ Z1 < e1, . . . , fl−1 ≤ Zl−1 < el−1, Zl ≥ el | τ).
Similarly, the probability of not rejecting H0 for any τ is
P (Accept H0 | τ) =
L∑
l=1
P (Accept H0 at stage l | τ),
= P (Zl < fl | τ)
+
L∑
l=2
P (f1 ≤ Z1 < e1, . . . , fl−1 ≤ Zl−1 < el−1, Zl < fl | τ).
As before, the expected sample size for any τ is given by
E(N | τ) =
L∑
l=1
{P (Reject H0 at stage l | τ) + P (Accept H0 at stage l | τ)} (ln+ rln).
Moreover, these probabilities can again be computed using multivariate normal in-
tegration. Using our notation from earlier, we have for example
P (Reject H0 at stage 2 | τ) =
∫ e1
f1
∫ ∞
e2
φ{x, τI1/22 ,Σ2} dx2dx1.
In some situations, a one-sided test will be more appropriate because departures from
H0 in one direction are implausible. Alternatively, it may be the case that we are inter-
ested in directly testing the superiority of one treatment over another. Consequently,
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much research has gone in to determining designs that will have desired operating char-
acteristics (now, a type-I error rate of α when τ = 0, and a type-II error rate of β when
τ = δ) and favourable performance in terms of the expected sample size. Below, we
discuss two popular methods, available for implementation via our commands.
4.2 Power Family of One-Sided Designs
In addition to their power family of inner wedge designs, Pampallona and Tsiatis (1994)
also detailed a one-parameter family of designs for one-sided tests, with boundaries given
by
el = Ce(l/L)
∆−1/2,
fl = δI
1/2
l − Cf (l/L)Ω−1/2.
As before, taking a final information level of
IL =
(Ce + Cf )
2
δ2
,
ensures that fL = eL as desired, and a two-dimensional grid search can be used to
determine the appropriate values of Ce and Cf . Our command powerFamily is available
to perform these computations.
4.3 Triangular Test
Whitehead and Stratton (1983) and Whitehead (1997) also proposed a triangular test
for one-sided group sequential clinical trial designs. Specifically, they proposed
el =
{
2
δ˜
log
(
1
2α
)
− 0.583
(
IL
L
)1/2
+
δ˜
4
l
L
IL
}
1
I
1/2
l
,
fl =
{
−2
δ˜
log
(
1
2α
)
+ 0.583
(
IL
L
)1/2
+
3δ˜
4
l
L
IL
}
1
I
1/2
l
,
with
δ˜ =
2z1−α/2δ
z1−α/2 + z1−β
,
and
IL =
[{
4(0.583)2
L
+ 8 log
(
1
2α
)}1/2
− 2(0.583)
L1/2
]2
1
δ˜
,
demonstrating this design would approximately attain the desired operating character-
istics.
This design has proven popular with trialists because of the speed with which it can
be calculated, and also because of its strong performance in terms of its expected sample
sizes (Wason and Jaki 2012). Our command triangular determines this design.
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5 Syntax
In this section, we detail the syntax of our six discussed commands, which are all
declared as rclass
doubleTriangular,
[
l(integer 3) delta(real 0.2) alpha(real 0.05)
beta(real 0.2) sigma(numlist) ratio(real 1) performance *
]
haybittlePeto,
[
l(integer 3) delta(real 0.2) alpha(real 0.05) beta(real
0.2) sigma(numlist) ratio(real 1) performance *
]
innerWedge,
[
l(integer 3) delta(real 0.2) alpha(real 0.05) beta(real
0.2) sigma(numlist) ratio(real 1) omega(real 0.5) performance *
]
powerFamily,
[
l(integer 3) delta(real 0.2) alpha(real 0.05) beta(real
0.2) sigma(numlist) ratio(real 1) omega(real 0.5) performance *
]
triangular,
[
l(integer 3) delta(real 0.2) alpha(real 0.05) beta(real
0.2) sigma(numlist) ratio(real 1) performance *
]
wangTsiatis,
[
l(integer 3) delta(real 0.2) alpha(real 0.05) beta(real
0.2) sigma(numlist) ratio(real 1) omega(real 0.5) performance *
]
Here, the prescribed options denote the following
alpha is the desired overall type-I error rate, α. That is, it is the two-sided or one-sided
type-I error rate according to the chosen command.
beta is the desired type-II error rate, β.
delta is the clinically relevant difference at which we power, δ.
l is the maximum number of allowed stages in the design, L.
omega is the shape parameter of the boundaries of the power family and Wang-Tsiatis
designs.
performance specifies that the performance of the identified design, i.e. its expected
sample size and power curves, should be determined and plotted.
ratio is the desired ratio r of the sample sizes between arms 0 and 1.
sigma is the standard deviation of the responses in arms 0 and 1; σ0 and σ1. This can
either be of length two, containing the assumed values of these two parameters, or
of length one, implying σ0 = σ1.
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Attainable via return list for all six commands, are the determined exact re-
quired group size n (r(n)), and the stopping boundaries a, r, e and f as appropri-
ate (e.g., r(a)). In addition, the vector of information levels I (r(I)), the covari-
ance matrix Λ (r(Lambda)), and a vector summarising the performance of the design
(r(performance))
(P (Reject H0 | 0), E(N | 0), P (Reject H0 | δ), E(N | δ),maxτE(N | τ),maxN)T ,
are available.
Note that in all of these commands, required one dimensional numerical searches are
performed using a purpose built implementation of Brent’s algorithm (Brent 1973). In
contrast, all two dimensional numerical searches are carried out with the Nelder-Mead
option in optimize().
6 Example 1: Two-Sided Tests
As our first example, we consider the case L = 2, α = 0.05, β = 0.2, δ = 0.2, σ0 = σ1 =
2, and r = 1, in two-sided testing.
We begin by demonstrating how doubleTriangular can be used to determine the
boundaries and sample size required by the Double Triangular test of Whitehead and
Stratton (1983). Explicitly, the following code is used to determine the design
. doubleTriangular, l(2) alpha(0.05) beta(0.2) delta(0.2) sigma(2) r(1)
2-stage Group Sequential Trial Design
The hypotheses to be tested are as follows:
H0: tau = 0 H1: tau != 0,
with the following error constraints:
P(Reject H0 | tau = 0) = .05,
P(Reject H0 | tau = delta = .2) = 1 - .2.
Double-triangular boundaries selected....................
...now determining design...................................
...design determined. Returning the results.................
...Exact required group sizes for each arm determined to be:
875.5 and 875.5.
...Rejection boundaries r determined to be:
(2.2,2.07).
...Acceptance boundaries a determined to be:
(.73,2.07).
...Operating characteristics of the design are:
P(Reject H0 | tau = 0) = .0531,
P(Reject H0 | tau = .2) = .8003,
E(N | tau = 0) = 2514.6,
E(N | tau = .2) = 2550.5,
max_tau E(N | tau) = 2716.4,
max N = 3501.9.
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As can be seen, by default the commands return an informative summary of the
chosen testing framework, their progress, and the characteristics of the final design.
Specifically, the first few lines describe the hypotheses that will be tested based on
the chosen command. The input values of alpha and beta are then used in printing
a summary of the desired operating characteristics. Several lines then follow which
describe the progress of the command in completing its required computations. Next,
the exact required number of patients in each arm, in each stage, are printed. The
rejection and acceptance boundaries then follow, along with a summary of the operating
characteristics of the identified design. In this case we see the design has a type-I error-
rate of 0.053, and power of 0.800. This is a well-known limitation of the double triangular
design: the type-I and type-II error requirements are only approximately achieved. The
final four printed results summarise various important sample size characteristics of the
design: the expected sample size when τ = 0, that when τ = δ, the maximum expected
sample size over all possible values of τ , and the maximum possible required sample
size. We can see that in this case, whilst the maximum possible value of N is 3501.9,
we would expected to not require more than 2716.4 patients.
Being able to easily determine this design is useful, however in most situations it is
unlikely that a trialist will have a single design in mind. Consequently, it is important to
be able to determine the performance of several designs and compare them graphically.
Here, we demonstrate this for the power family of inner wedge designs. Using the
following code, we find the designs for Ω = −0.5, −0.25, 0 and 0.25, saving their
performance. Then, we combine the saved graphs to produce Figure 1
. qui innerWedge, l(2) alpha(0.05) beta(0.2) delta(0.2) sigma(2) omega(-0.5) r(1)
> perf saving(firstDesign) nodraw title({&Omega} = -0.5) scale(0.75) scheme(sj)
. qui innerWedge, l(2) alpha(0.05) beta(0.2) delta(0.2) sigma(2) omega(-0.25) r(1)
> perf saving(secondDesign) no draw title({&Omega} = -0.25) scale(0.75) scheme(sj)
. qui innerWedge, l(2) alpha(0.05) beta(0.2) delta(0.2) sigma(2) omega(0) r(1) perf
> saving(thirdDesign) nodraw title({&Omega} = 0) scale(0.75) scheme(sj)
. qui innerWedge, l(2) alpha(0.05) beta(0.2) delta(0.2) sigma(2) omega(0.25) r(1)
> perf saving(fourthDesign) nodraw title({&Omega} = 0.25) scale(0.75) scheme(sj)
. graph combine firstDesign.gph secondDesign.gph thirdDesign.gph fourthDesign.gph,
> ycommon scheme(sj)
We observe that increasing the value of Ω appears to reduce the expected sample
required when |τ | is small. However, this comes at a cost to that required when |τ | is
large.
7 Example 2: One-Sided Tests
As our next example, we consider one-sided testing. We take L = 3, α = 0.1, β =
0.1, δ = 0.25, σ0 = 1, σ1 = 2 and r = 2. Similarly to the above, we demonstrate
how powerFamily can be used to determine several designs (Ω = −0.25, Ω = 0, and
Ω = 0.25), and in addition compute the boundaries and sample size of the triangular
test. Saving the performance of each, we then compare their performance graphically,
12 Group Sequential Trial Design
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Figure 1: Comparison of the performance of several two-sided power family of inner
wedge designs.
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creating Figure 2 with the following code
. qui powerFamily, l(3) alpha(0.1) beta(0.1) delta(0.25) sigma(1, 2) omega(-0.25)
> r(2) perf saving(firstDesign) nodraw title(Power family with {&Omega} = -0.25)
> scale(0.75) scheme(sj)
. qui powerFamily, l(3) alpha(0.1) beta(0.1) delta(0.25) sigma(1, 2) omega(0) r(2)
> perf saving(secondDesign) nodraw title(Power family with {&Omega} = 0)
> scale(0.75) scheme(sj)
. qui powerFamily, l(3) alpha(0.1) beta(0.1) delta(0.25) sigma(1, 2) omega(0.25)
> r(2) perf saving(thirdDesign) nodraw title(Power family with {&Omega} = 0.25)
> scale(0.75) scheme(sj)
. qui triangular, l(3) alpha(0.1) beta(0.1) delta(0.25) sigma(1, 2) r(2) perf
> saving(fourthDesign) nodraw title(Triangular test) scale(0.75) scheme(sj)
. graph combine firstDesign.gph secondDesign.gph thirdDesign.gph fourthDesign.gph,
> ycommon scheme(sj)
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Figure 2: Comparison of the performance of several one-sided power family designs and
the triangular test.
As has been reported previously, the triangular test does indeed fare well in compar-
ison to the two identified power family designs. Explicitly, it has the lowest maximum
expected sample size of the four designs. However, this does come at the cost of an
increased maximum possible sample size, as evidence by its performance for large |τ |.
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8 Conclusion
It is important that any clinical trial control both its type-I and type-II error rates
accurately. For this task, Stata introduced in Version 13 the command power, which
can be used for an extremely wide array of trial scenarios. However, as we have dis-
cussed, group sequential clinical trial designs are extremely popular with researchers,
and to date few available commands are available in Stata for determining such de-
signs. Notable exceptions include nstage (Barthel et al. 2009; Bratton et al. 2015) and
nstagebin (Bratton 2014) for multi-arm multi-stage trial designs with time-to-event
and binary endpoints respectively. In addition, the command simsam can determine
the required sample size of certain group sequential clinical trial designs given stopping
boundaries (Hooper 2013). There are no established commands however for determin-
ing the boundaries and group size required by the wide array of group sequential trial
designs for normally distributed outcomes discussed here.
Several extensions to our commands are now possible. We have assumed that the
variance of the responses on both treatment arms is known prior to trial commencement.
Whilst this is a common assumption in the group sequential design literature, often this
will be a strong one to make. However, Whitehead et al. (2009) proposed a simple
quantile substitution method for dealing with this problem, which has been shown to
generally control the type-I error rate to the correct level (Wason et al. 2012). This would
no doubt be a useful addition to our commands. Moreover, we have assumed that the
interim analyses are equally spaced in-terms of the number of patient responses accrued
in each arm. Lan and DeMets (1983) proposed an error spending approach to the design
of group sequential trials that allows this assumption to be relaxed. Consequently, a
command to employ such methodology could prove useful to those seeking more complex
designs.
Additionally, our focus has been on two-arm trials. Today, multi-arm multi-stage
trials are becoming increasingly popular. Therefore, extending these designs to allow
for multiple experimental arms would be advantageous. Finally, there have now been
several proposals for the determination of optimal or near-optimal group sequential
designs (see, for example, Wason and Jaki (2012), Wason et al. (2012), and Wason
(2015b)). To allow trialists to maximise the efficiency gains made by utilising a group
sequential design, the establishment of commands for determining such designs would
be highly advantageous.
Regardless of these possible expansions, our commands can be used to determine
stopping boundaries, exact required group sizes, and also to compare the performance
of a selection of designs. Consequently, they should prove useful to those seeking to
exploit the efficiencies of a group sequential design whilst working in Stata.
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